Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia

A novel therapeutic approach in cancer, attempting to stimulate host anti-tumor immunity, involves blocking of immune checkpoints. Lymphocyte activation gene 3 (LAG3) is an immune checkpoint receptor expressed on activated/exhausted T cells. When engaged by the major histocompatibility complex (MHC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Mika, Herishanu, Yair, Katz, Ben-Zion, Dezorella, Nili, Sun, Clare, Kay, Sigi, Polliack, Aaron, Avivi, Irit, Wiestner, Adrian, Perry, Chava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477606/
https://www.ncbi.nlm.nih.gov/pubmed/28154084
http://dx.doi.org/10.3324/haematol.2016.148965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477606/
https://www.ncbi.nlm.nih.gov/pubmed/28154084
http://dx.doi.org/10.3324/haematol.2016.148965

Ejemplares similares